CClinicalTrials.gg
RecruitingNCT06712758Updated Dec 2, 2024

Low Intraocular Pressure Cataract Surgery With Zeiss Quatera in Glaucoma Patients

An observational study in Cataract and Glaucoma, sponsored by Visionair Oogzorg. Recruiting at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Visionair Oogzorg · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
10
Sex
All
01

Study summary

You were selected to participate in this observational study because you suffer from glaucoma and cataracts. For the cataract you will have cataract surgery. This study will not affect your treatment, it will only collect data on what is performed before, during and after the procedure.

The aim of this data collection is to demonstrate the safety of a new generation of cataract surgical devices in patients who also suffer from glaucoma. They are glaucoma patients who have an increased sensitivity to eye pressure increases both during and after surgery. The new surgical device makes it possible to safely perform cataract surgery under low pressures. This could, at least theoretically, provide an advantage for patients who also suffer from glaucoma.

Read the detailed description

Cataract surgery is a highly standardized procedure. However a new phacoemulsification system "Quatera 700" has been developed by Carl Zeiss Meditec. The system has a unique patented QUATTRO Pump that directly controls infusion and aspiration and enables a synchronous change in both. It has four membranes, which directly regulate infusion and aspiration and maintain a pre-set intraocular pressure (IOP), resulting in a stable anterior chamber during the surgery. The membranes are activated by pneumatic pressure regulated by sensors that measure infusion and aspiration flows which allows the system to determine and compensate for incisional leakage as well. This innovative pump system allows surgeons to significantly decrease the intra-ocular pressure during cataract surgery. In respect to competitive devices on the market, the Quatera system is able to operate with pressure four times lower than average. Especially in glaucoma patients (patients suffering from optic nerve head damage due to elevated intraocular pressures), performing surgery with lower intra-ocular pressures would help in avoiding extra nerve fiber layer damage and overall safety of the surgery.

02

Conditions studied

  • Cataract
  • Glaucoma

Keywords

  • intra ocular pressure
  • cataract
  • Quatera
  • glaucoma
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from Dr. Koen Willekens at Visionair Oogzorg.

Inclusion criteria

  • Patients diagnosed with glaucoma that are diagnosed with age-related cataract

Exclusion criteria

Exclusion Criteria:

  • Unwilling to sign informed consent
  • Functionally monophtalmic patient
  • Endothelial dystrophy
  • Active uveitis
  • Known corticosteroid responder
  • Presence of uncontrolled systemic disease
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Glaucoma patients in need of cataract surgery

    Cataract surgery

05

What researchers measure

Primary outcomes

  1. Complication rate during cataract surgery

    Complication rate during cataract surgery

    Time frame: Month 1

Secondary outcomes

  1. Best corrected visual acuity

    Best corrected visual acuity will be determined and recorded at the preoperative, day 1, week 1 and month 1 visit.

    Time frame: Month 1

  2. Intraocular pressure

    The intraocular pressure will be measured at the preoperative, day 1, week 1 and month 1 visit. Ocular hypertension will reported.

    Time frame: 1 month

  3. Retinal nerve fiber layer thickness

    Optical Coherence Tomography will be performed at the preoperative and month 1 visit. Any abnormalities will be described.

    Time frame: 1 year

  4. Visual field mean deviation

    The visual field examination will be performed at the preoperative and month 1 visit. Any abnormalities will be described.

    Time frame: Month 1

06

Study locations

1 of 1 sites recruiting
  • Visionair Oogzorg
    Geel, 2400, Belgium
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06712758
Lead sponsor
Visionair Oogzorg
Responsible party
Koen Willekens (Professor Doctor, Visionair Oogzorg) — Principal investigator
First posted
Dec 2, 2024
Start date
Nov 12, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 2, 2024

Study contacts

Koen Willekens, Prof
Contact
kw@visionairoogzorg.be
003214808311
Sien Boons
Contact
sb@visionairoogzorg.be
003216715634
Koen Willekens
principal investigator · Visionair Oogzorg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion